AD Mechanism of Action (MoA) Studies

Creative Biolabs offers a full range of advanced in vivo, in vitro, and ex vivo technologies and platforms that enable researchers to explore the AD MoAs and thus drive drug development from early discovery to the preclinical stage.

Background of Alzheimer's Disease Studies

Alzheimer's disease (AD) is a progressive neurodegenerative disease, causing brain atrophy and brain cell apoptosis, eventually leading to dementia and death. It is characterized by extracellular amyloid-beta (Aβ) plaques and intracellular aggregation of neurofibrillary Tau tangles, synaptic loss, and dysfunction, neuroinflammation, infection enhanced oxidative stress and dysfunction of metabolism, and bioenergetics. There is currently no effective direct treatment for AD. Therefore, a novel therapy that can effectively delay the onset or reverse the progression of the disease is an urgent need. Launching research on the mechanisms of action (MoAs) in AD is a promising opportunity to find innovative treatments.

AD Mechanism of Action

Understanding the pathogenesis of Alzheimer's disease is of vital importance for drug development. The aggregation of Aβ peptides and soluble Aβ oligomers causes toxicity to synapses and neurons. Another hallmark of AD is the tau protein hyperphosphorylation and aggregation. Tau phosphorylation is considered to be a potential contributor to forming neurofibrillary tangles. The aggregation of intracellular neurofibrillary tau tangles, especially pairs of helical filaments (PHF), is cytotoxic to neurons. The function of synaptic plasticity, synaptic neurotransmission, and neuroprotection is hence defective, resulting in enhanced neuroinflammation and oxidative stress. Another hypothesis is based on direct or indirect microbial infection. Based on AD MoA studies, researchers could develop disease-modifying treatments that enhance cognitive abilities or make positive influences on amyloid or Tau.

Fig.1 Pathophysiology of Alzheimer's disease. (Dhapola, 2021)

AD Mechanism of Action Studies at Creative Biolabs

Creative Biolabs' in vivo, in vitro, and ex vivo assay platform provides comprehensive types of cell culture models as well as transgenic and aged animal models, along with our advanced high-throughput imaging tools, electrophysiology tools, and behavioral testing platforms, enabling the developers to obtain a large amount of reliable research data for application in neuroscience studies. These assays make it possible for researchers to explore the mysteries of AD MoAs and thus validate the symptomatic and/or disease-modifying effects of drugs on AD.

If you have the intention to learn more information about AD MoA studies, please don't hesitate to contact us. Our team will get back to you as soon as possible.

For further details about AD MoA studies, please click the following links:

• Amyloid Targeting Therapies Study
• Tau Targeting Therapies Study
• Synaptic Plasticity/Neuroprotection Targeting Therapies Study
• Inflammation/Infection Targeting Therapies Study
• Neurotransmitter Receptors Targeting Therapies Study
• Gut-brain Axis Targeting Therapies Study
• Oxidative Stress Targeting Therapies Study
• Metabolism and Bioenergetics Targeting Therapies Study

Reference

1. Dhapola, R.; et al. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease. Inflammopharmacology. 2021: 1-13.